[go: up one dir, main page]

WO2012003562A4 - Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués - Google Patents

Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués Download PDF

Info

Publication number
WO2012003562A4
WO2012003562A4 PCT/BR2011/000220 BR2011000220W WO2012003562A4 WO 2012003562 A4 WO2012003562 A4 WO 2012003562A4 BR 2011000220 W BR2011000220 W BR 2011000220W WO 2012003562 A4 WO2012003562 A4 WO 2012003562A4
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
composition according
antineoplastic
cyclodextrin
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2011/000220
Other languages
English (en)
Portuguese (pt)
Other versions
WO2012003562A8 (fr
WO2012003562A1 (fr
Inventor
Renata Barbosa De Oliveira
Ricardo José Alves
Maria Betânia FREITAS MARQUES
Mônica CRISTINA DE OLIVEIRA
Cristina Duarte Vianna Soares
Lucas REIS FELÍCIO
Elaine Amaral Leite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SILVIA LOPES MARCELA
Universidade Federal de Minas Gerais
Original Assignee
SILVIA LOPES MARCELA
Universidade Federal de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SILVIA LOPES MARCELA, Universidade Federal de Minas Gerais filed Critical SILVIA LOPES MARCELA
Publication of WO2012003562A1 publication Critical patent/WO2012003562A1/fr
Publication of WO2012003562A4 publication Critical patent/WO2012003562A4/fr
Anticipated expiration legal-status Critical
Publication of WO2012003562A8 publication Critical patent/WO2012003562A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques antinéoplasiques contenant un nitroimidazol substitué. Ces compositions peuvent être utilisées dans le traitement de néoplasies au stade initial ou en combinaison avec des médicaments à activité antitumorale déjà établie à des stades plus avancés de la maladie.
PCT/BR2011/000220 2010-07-07 2011-07-07 Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués Ceased WO2012003562A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI1003297-5 2010-07-07
BRPI1003297-5A BRPI1003297A2 (pt) 2010-07-07 2010-07-07 composições farmacêuticas antineoplásicas contendo compostos nitroimidazóis substituìdos

Publications (3)

Publication Number Publication Date
WO2012003562A1 WO2012003562A1 (fr) 2012-01-12
WO2012003562A4 true WO2012003562A4 (fr) 2012-03-29
WO2012003562A8 WO2012003562A8 (fr) 2013-07-04

Family

ID=45440721

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000220 Ceased WO2012003562A1 (fr) 2010-07-07 2011-07-07 Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués

Country Status (2)

Country Link
BR (1) BRPI1003297A2 (fr)
WO (1) WO2012003562A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445963A1 (de) * 1962-04-06 1969-12-04 Klosa Dipl Chem Dr Josef Verfahren zur Herstellung eines neuen Imidazolderivates
US5929104A (en) * 1997-04-02 1999-07-27 Pola Chemical Industries, Inc. Method for inducing apoptosis of cancer cell
KR20030067275A (ko) * 2002-02-07 2003-08-14 주식회사 하이폭시 니트로이미다졸 및 위상 이성질화 효소 저해제를유효성분으로 포함하는 항암제
WO2010047831A1 (fr) * 2008-10-23 2010-04-29 Nycomed Us Inc. Formulations de gel de métronidazole stables

Also Published As

Publication number Publication date
WO2012003562A8 (fr) 2013-07-04
WO2012003562A1 (fr) 2012-01-12
BRPI1003297A2 (pt) 2012-04-10

Similar Documents

Publication Publication Date Title
Ishiwata et al. Synthesis of docosasaccharide arabinan motif of mycobacterial cell wall
CA2753641C (fr) Compositions de cyclopolysaccharide et de bendamustine
US12285441B2 (en) Uses of glycosaminoglycan conjugates
BR112012002709A2 (pt) formulações de liberação controlada de muteínas de lipocalina
WO2010039762A3 (fr) Compositions pharmaceutiques comprenant des composés d'acide boronique
CN106580971B (zh) 一种药物组合物及其制备方法
RU2015134583A (ru) Фармацевтические композиции, содержащие доноры нитроксила
WO2012003562A4 (fr) Compositions pharmaceutiques antinéoplasiques contenant des nitroimidazols substitués
WO2012003563A4 (fr) Compositions pharmaceutiques antinéoplasiques contenant des composés nitroaromatiques substitués
RU2010101930A (ru) Производные нистатина и их применение в качестве противогрипковых агентов
AU2010247814B2 (en) Lipid-polymer conjugates, their preparation and uses thereof
CZ2008528A3 (cs) Deriváty triterpenoidu pro lécbu nádorových onemocnení a farmaceutická kompozice je obsahující
JP2015533128A5 (fr)
RU2015117641A (ru) Новые соединения флавоноидов и их применение
US10314811B2 (en) Compositions and methods for selectively inhibiting intestinal carboxylesterase 2 enzyme activity
WO2014030974A1 (fr) Agent anticancéreux à base de nanotubes de carbone supprimant la résistance des cellules cancéreuses
KR20120120712A (ko) 헤파린-도세탁셀-토로콜산 접합체로 이루어진 표적성이 향상된 수용성 항암제 및 그의 제조방법
WO2017174847A1 (fr) Nouveaux excipients pour la transfection de micro-arn
WO2021011488A1 (fr) Compositions comprenant du chlorhydrate d'aldoxorubicine et de l'ifosfamide et leur utilisation pour le traitement d'un sarcome de tissu mou
JPWO2005077382A1 (ja) プリオン増殖抑制剤
RU2013134249A (ru) Фармацевтические композиции производных пиридиния и хинолиния

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11803033

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11803033

Country of ref document: EP

Kind code of ref document: A1